Summary
This study examined the effects of the long-acting selective mini somatostatin analogue (SMS) 201-995 in two acromegalic patients who were treated for 3 and 6 months, respectively. During treatment the mean growth hormone levels (25.3 and 20.8 ng/ml vs 5.9 and 10.6 ng/ml) and somatomedin C levels (6.2 and 6.2 IU/ml vs 3.3 and 3.8 IU/ml) decreased and the patients reported an improvement in their symptoms. The main side effect was an increase in stool fat excretion which did exceed the normal range (<7 g/day) in one patient. Five acromegalics who received 2 × 50 µg SMS 201-995/day for 5 days showed a significant increase of stool fat excretion (1.7 vs 3.5 g/day;p<0.05). Fasting blood glucose levels, glucose tolerance, and glycosylated hemoglobin were not essentially effected. It is concluded that SMS 201-995 offers new possibilities in the treatment of acromegaly. The gastrointestinal and diabetogenic side effects of this substance, however, should be carefully monitored.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- GH:
-
growth hormone
- HbA1 :
-
glycosylated hemoglobin
- OGTT:
-
oral glucose tolerance test
- SMS:
-
selective mini somatostatin
- TRH:
-
thyrotropin-releasing hormone
- TSH:
-
thyroid-stimulating hormone
References
Alpers DH (1983) Absorption of water-soluble vitamins, folate, minerals, and vitamin D. In: Sleisenger MH, Fordtran JS (eds) Gastrointestinal Disease. WB Saunders, Philadelphia London Toronto
Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J (1982) SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140
Brazeau O, Vale W, Burgus R, Ling N, Rivier J, Guillemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77–79
Ch'ng LJ, Sander LM, Kraenzlin ME, Burrin JM, Joplin GM, Bloom SR (1985) Long term treatment of acromegaly with a long acting analogue of somatostatin. Br Med J 290:284–285
Clemmons DR, van Wijk JJ, Rigdway ED, Kliman B, Kjellberg RN, Underwood LE (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. New Engl J Med 301:1138–1142
Del Pozo E, Schlüter K, Neufeld M, Tortosa F, Marbach P, Wendel L, Kerp L (1986) Endocrine profile and pharmacokinetics of the new somatostatin analog SMS 201–995. Acta Endocrinol (Kbh) (in press)
Hall R, Besser GM, Schally AV, Coy DH, Evered D, Goldie DJ, Kastin AJ, McNeilly AS, Mortimer CH, Phenekos C, Tunbrigde WMG, Weightman D (1973) Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet II:581–584
Kraenzlin ME, Ch'ng JL, Wood SM, Carr DH, Bloom SR (1985) Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88:185–187
Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E (1985) The somatostatin analogue SMS 201–995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161–1165
Maton PN, O'Dorisio TM, Howe BA, McArthur KE, Howard JM, Cherner JA, Malarkey TB, Collen MJ, Gardner JD, Jensen RT (1985) Effect of a long-acting somatostatin analogue (SMS 201–995) in a patient with pancreatic cholera. New Engl J Med 312:17–21
Mayer TK, Freedmand ZR (1983) Protein glycosylation in diabetes mellitus — a review of laboratory measurements and their clinical utility. Clin Chim Acta 127:147–184
Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E (1984) Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet II:782–784
Plewe G, Nölken G, Krause U, del Pozo E, Beyer J (1986) Somatostatin analogue SMS 201–995 in Type I diabetes mellitus: initial experience after repeated administration. Scand J Gastroenterol [Suppl] (in press)
Quabbe HJ (1982) Treatment of acromegaly by trans-sphenoidal operation, 90-Yttrium implantation and bromocriptine: results in 230 patients. Clin Endocrinol 16:107–119
Schaison G, Couzinet B, Moatti N, Pertuiset B (1983) Critical study of the growth hormone response to dynamic tests and the insulin growth factor assay in acromegaly after microsurgery. Clin Endocrinol 18:541–549
Van de Kamer JH, ten Bokkel Heunik H, Weyers HA (1949) Rapid method for the determination of fat in faeces. J Biol Chem 177:347–354
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Plewe, G., Schrezenmeir, J., Nölken, G. et al. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 over 6 months. Klin Wochenschr 64, 389–392 (1986). https://doi.org/10.1007/BF01728190
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01728190